Jun Xu Email

Senior Director, Translational Science . Verismo Therapeutics

Current Roles

Employees:
31
Revenue:
$2.4M
About
Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options. Verismo Therapeutic’s core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T cells and NK cells. Preclinical studies show that SynKIR™-T cells, created by introducing these KIR-based CARs (KIR-CARs) into T cells, more effectively eliminate aggressive tumors in vivo when compared with T cells bearing traditional 2nd generation CAR designs found in current FDA approved CAR-T cell therapies.
Verismo Therapeutics Address
3675 Market St
Philadelphia, PA
United States
Verismo Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.